IRCT20210213050348N1 IRCT 2021-05-01 Research Department of Alborz University of Medical Sciences Clonidine vs tizanidine for withdrawal syndrome Comparison between clonidine and tizanidine as adjuvant therapy in managing opioid withdrawal syndrome in toxicology icu in Kosar hospital of Karaj and Loghman Hakim hostpital of Tehran 2021-03-21 anticipated 100 Complete https://irct.ir/trial/54313 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, a number is assigned to each participant and then the numbers are evenly divided into two blocks of clonidine or tizanidine by Random allocation software using simple block randomization method. For this purpose, after installing the program, we determine the number of groups, the sample size and the name of each group. Then, the software places patients with different codes in different groups according to the size of the groups, Blinding description: The patients who are hospitalized in these wards don't have a high level of consciousness and if the family gives consent, they will enter into the project. In this case the patients and their families won't be aware of the group of the patient. The medicine will be administered without label and with exact similar appearance therefore the patients cannot guess their medicine. The data will be encrypted and the person who analyzes the data won't be aware of the groups of the patients. 2-3 Opioid withdrawal syndrome. Intervention group: Methadone and Tizanidine. Methadone from pharmaceutical company, 5mg q12h. Tizanidine from Aboureyhan pharmaceutical company, 4mg q12h , will be increased upto twice if signs are not relieved. Both will be administered intravenously until the patient is discharged.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No further info is present.